One of the current problems is one, but who's been in the # 39; developed for a long time, in a public and public health, a & # 39; Most older people are older. In America, projections indicate that the number of people older than 65 can be doubled by 2025, with a proportional increase in the problems associated with that level of life.
Our country is responsible for this move. In the last National Census (2010), there were six million adults over 60 years (Argentina, 14%) in Argentina. This figure takes us within the countries with the highest percentage of older people in the region.
If we take into account that dementia in general, and Alzheimer's disease in particular, are diseases around the world, the biggest effort of researchers today is to be a & # 39; confirming the things that increase their risk of suffering and working on them. to be able to stop them.
The final test of Alzheimer's was tested during the test after death, although progress has been made in the treatment and early detection of recent years. Obtaining changes in brain devices related to early dementia levels was one of the recent advances of Pablo Scodeller and Aman Mann made at the Erkki Ruoslahti laboratory at the University of California , San Diego, United States.
Scodeller, a Mendoza who has been studying and receiving a PhD in Argentina, tells us about finding CTGF (a factor of becoming a prophecy associated), a protein that is deposited in the blood vessels of blood in the brain in early stages of Alzheimer's.
"We found that the CTGF protein begins to collect in the vessels of cerebral blood even before beta-amyloid records, which are similar to Alzheimer's disease," says Scodeller. A good source to bring this ball forward
The article, published in it Natural Communications it also describes a short sequence of amino acids or peptide, known as "DAG", which has an accrual to CTGF. The DAG can be inserted into blood blood, where it is quickly detected for its partner, CTGF.
This is very important to make their judgments easier, because DAG is capable of managing small fragments of iron oxide, a thousand times less than cells, to the place that affects them. The collection of these elements creates the appearance of magnetic tomography, which is a. help dentists and researchers to find and their; defines the amount of their damage. For Scodeller, DAG may find Alzheimer's disease much earlier than cover agents currently agreed for clinical use.
The DAG peptide can be accompanied by, not only as a companion for diagnosis, but also a thermal drug.
"Now you can take the CTGF and do it by designing a few cells that attach to an important site of this protein and so remove removal. You can not add an antibody to to prevent it, "said Scodeller. "Another medicinal option is to prevent CTGF synthesis in the two types of cells that do it, the blood cells of the blood of the brain and the astrocytes, a type of brain cells, although the second make a harder one than its "first" add
Another main point of finding is that CTGF is open in the blood vessels, that is, in contact with the blood, so that all medicinal or critical outcomes that are damaged by blood. "Not only does he need to go into the woven or go into the chill, which is hard to achieve, to reach his target," Scodeller continues.
Although the study was carried out in mouse and disease models, DAG researchers found CTGF in a medical sample from Alzheimer's patient, which is relevant from the translation opinion. "The CTGF presence is at an early stage of the disease opening the door for diagnosis and treatment," Scodeller says, "there is a CTGF that appears in blood vessels of Alzheimer's disease diseases long before I & # 39; mentally extinguished the brain for the disease. "
Scodeller won a Tartu University, Estonia, to continue his research, but the San Diego team worked to produce the clinic based on its concept of " focus on this target (CTGF), from either the use of peptides, small molecules or antibodies, or to develop or diagnose the diagnosis.
For this reason they established a biotechnology company (AivoCode, https://aivocode.com), which holds the patent license. AivoCode is a scientist orientation and is a boot machine in & # 39; Developing innovative technologies and a broad platform to improve diagnosis and treatment of patient diseases.
The results of this survey are encouraging. Alzheimer's disease has been catastrophic for the patient and the family, and no one should let it undoubtedly.
Root with social social impact
Situated as the third disease in social health costs after ischemic heart disease and cancer, Alzheimer's disease has become an increasingly common disease of global level. According to official data, 0.5% of the world's population are living today with dementia, a number that will Increasingly amazing. There are about 36 million people suffering from this disease, a figure that reaches more than 115 million by 2050.
In Argentina, a level of dementia in general is estimated at 12.2% in subjects over 65 years. According to these figures, we can include that there are more than 600 thousand people with dementia in the country, and about 60% of them are the Alzheimer's type (360 thousand subjects). If we add relatives and people involved in patient care, the side of the population's impact has been difficult.
The illness also has a severe pressure in the economy. According to official statements, it costs billions of the world and it is a problem of a drug problem before the end of this year.
They considered irregular in the patient's brain
When underneath the microscopic look, Alzheimer's patient's brain brain is two types of diabetes; diversity considered to be a species of illness. Here are the following:
They are assemblies of a protein called "beta-amyloid" that is damaged and damaged. destroy neurons in the brain. Although the last case of the neurons' death does not know, beta-amyloid collection outside the brain cells is the most suspected person.
Neurons are responsible for a transport system and internal support that improves nutrition and other essential products throughout the long expansion. This system needs the current prost structure and operation called "Tau".
In Alzheimer's disease, Tau shrub threads are cut off by a & # 39; Making real blades in brain cells, that is the reason why the transport system fails and is another reason that fails; contribute to the death of neurons.
The original text of this article was published on 11/26/2018 in our print argument.